Partner

Articles & Insights / Laboratory Quality

Investigating OOS and OOT Results with Scientific Discipline

An unexpected laboratory result is a quality signal that requires an evidence-based response. The investigation should determine what the result means, whether the cause extends beyond the tested sample and how recurrence will be prevented.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Recognise two different signals
  • Preserve the evidence
  • Test hypotheses rather than search for passing numbers

Recognise two different signals

An out-of-specification result falls outside established acceptance criteria. An out-of-trend result differs from an expected pattern even if it remains within specification. OOT criteria should be established through product and method understanding rather than used as a retrospective label for any inconvenient observation.

A hypothetical assay result of 97% may meet a specification yet warrant review if a stable process has consistently produced results near 100% and the shift exceeds expected variability. The decision depends on the measurement capability and historical context. OOT does not automatically mean batch failure, but it should not be ignored because a limit has not been crossed.

Preserve the evidence

Notify the appropriate supervisor and quality function promptly, retain relevant preparations when feasible and preserve instrument data and audit trails. Review whether the system and method performed as intended. Check calculations, standards, reagents, sample preparation, instrument condition and observations recorded during analysis.

FDA’s OOS guidance describes an initial laboratory assessment followed by a broader investigation when a clearly causative laboratory error has not been established. Contract laboratories should communicate their findings and supporting records to the responsible manufacturing quality unit. R17

Test hypotheses rather than search for passing numbers

A suspected cause should explain the magnitude and direction of the result and be supported by evidence. If incomplete extraction is proposed, design an experiment capable of examining extraction behaviour. If dilution error is suspected, review preparation records and use retained material where suitable. A possibility mentioned in a checklist is not an assigned cause.

Retesting should follow an approved, scientifically justified plan. Repeated analysis until a passing value appears introduces selection bias. A passing retest does not automatically invalidate the original result, and averaging a failure with passing results can obscure meaningful variation. Treat resampling as a separate decision requiring a rationale about sample representativeness.

Extend the investigation beyond the laboratory

When a laboratory cause is not demonstrated, examine manufacturing, materials, storage, transport and sampling. Review related batches, products and time periods according to the plausible scope. A rejected batch may still reveal a systemic issue that affects material already distributed or other work in progress.

For a hypothetical dissolution failure, evidence of correct apparatus performance directs attention toward the product but does not identify the root cause. Compare granulation, drying, compression, coating and packaging records with the release pattern. Use additional testing to answer defined questions rather than generate a large volume of unrelated data.

Make disposition transparent

The responsible quality unit should evaluate all relevant evidence, including the original result, investigation findings, additional testing and unresolved uncertainty. Clearly distinguish a documented invalid laboratory result from a confirmed product failure and from an inconclusive investigation. Each situation requires a reasoned disposition under the applicable quality system and regulatory obligations.

The illustration shows these outcomes as separate branches. It does not turn an inconclusive result into a presumptive pass. The investigation record should allow a reviewer to reconstruct why evidence supported the final decision.

Explore the scienceLaboratory Quality

Follow the evidence to a quality decision

Preserve evidenceReviewLaboratory errorProduct failureInconclusive
Preserve evidence

Retain relevant preparations, records, instrument data and audit trails.

Conceptual illustration. Select a topic to explore its role. The visual does not establish formulation performance or prescribe universal regulatory requirements.

An investigation can identify a laboratory cause, confirm a product failure or remain inconclusive. The quality decision must consider the complete evidence in each case.

Verify corrective action effectiveness

A corrective action should address the demonstrated cause. Training alone is a weak response when the procedure is ambiguous or equipment design creates repeated errors. Consider method clarification, process controls, maintenance or supplier action as appropriate. Define an effectiveness check with a relevant observation period and measurable outcome.

Stabicon can support structured laboratory investigations and trend review while providing clients with the data needed for their quality decisions. The laboratory’s technical conclusion and the manufacturer’s batch-disposition responsibilities should be clearly defined in the quality agreement.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R06
    ICH Q10 Pharmaceutical Quality System

    Final guideline, 2008. Pharmaceutical quality system and lifecycle management.

  2. R17
    FDA Investigating Out of Specification Test Results for Pharmaceutical Production

    Final guidance, May 2022. Laboratory investigations and evaluation of results.

  3. R18
    ICH Q9 R1 Quality Risk Management

    Final guideline adopted January 2023. Scientific and risk-based quality decisions.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin